Latest & greatest articles for ace inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ace inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ace inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ACE inhibitors

Angiotensin converting enzyme inhibitors (ACE) are principally used to reduce blood pressure. ACE inhibitors work by reducing the activity of the renin-angiotensin-aldosterone system. They have been used in a variety of conditions, including hypertension, acute myocardial infarctions, left ventricular systolic dysfunction and diabetic nephropathy

Ace inhibitors can be used alone to treat hypertension, or they can be used in combination with other drugs such as diuretics. Case studies and clinical trials on the medicine show that it can be used to prevent stroke or heart attacks. Common side effects of the drug including hypotension, dry cough, hyperkalaemia, headache, dizziness, fatigue, nausea, renal impairment and swelling in the lips and tongue.

ACE Inhibitors are widely used and feature extensively in the literature including clinical guidelines, systematic reviews, randomised controlled trials, case studies etc. These can easily be found via a search of the Trip Database. Medical research is vital to the development of new treatments and therapies for hypertension.

Top results for ace inhibitors

61. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials

Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials Kshirsagar A V, Joy M S, Hogan S L, Falk R J, Colindres R E Authors' objectives (...) To determine the efficacy of ACE inhibitors in slowing the progression of renal disease over a broad range of functional renal impairment. Searching MEDLINE was searched from January 1970 to June 1999 using a specialised MEDLINE search strategy (see Other Publications of Related Interest no.1). In addition, abstracts from the Annual American Society of Nephrology meetings were reviewed for the past 7 years to identify studies that might not yet have been published. Bibliographies of original articles

DARE.2000

62. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Flather M D, Yusuf S, Kober L, Pfeffer M, Hall (...) A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E Authors' objectives To assess the effects of angiotensin-converting enzyme (ACE) inhibitors in patients with left ventricular dysfunction or heart failure using data from individual patients. Searching MEDLINE was searched for relevant trials of ACE inhibitors in acute MI (the search terms and dates were not reported). Researchers and colleagues in the pharmaceutical industry were consulted, and the reference lists from review articles

DARE.2000

63. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial.

Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. 9872248 1999 01 19 1999 01 19 2015 06 16 0140-6736 352 9145 1998 Dec 19-26 Lancet (London, England) Lancet Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. 1978-81 Diabetes is a common cause of polyneuropathy. The development and progression of nephropathy (...) , retinopathy, and neuropathy are closely related. Angiotensin-converting enzyme (ACE) inhibitors delay progression of both nephropathy and retinopathy. We investigated the effect of ACE inhibition on diabetic neuropathy. We recruited 41 normotensive patients with type I or type II diabetes and mild neuropathy into a randomised double-blind placebo-controlled trial. Changes in the neuropathy symptom and deficit scores, vibration-perception threshold, peripheral-nerve electrophysiology, and cardiovascular

Lancet1999

64. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.

Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. 10406358 1999 07 30 1999 07 30 2015 06 16 0140-6736 354 9172 1999 Jul 03 Lancet (London, England) Lancet Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. 9-12 (...) The survival benefit from the use of inhibitors of angiotensin-converting enzyme (ACE) in patients with acute myocardial infarction is usually presented in terms of risk ratios and lives saved per 1000 people treated. A more relevant way to present the extent of benefit would be in terms of an increase in life expectancy, but this approach has not previously been possible because of limited data on long-term outcome. We aimed to calculate the effect of trandolapril on life expectancy with follow-up data

Lancet1999

65. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation

Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation Kiberd B A, Jindal K K Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for microalbuminuria, hypertension and macroproteinuria and routine treatment of insulin-dependent diabetic patients (IDDM) with angiotensin-converting enzymes (ACEs). The treatment with ACE inhibition is equivalent to captopril 25 mg three times a day. If two of three

NHS Economic Evaluation Database.1998

66. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy

Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy Garattini L, Brunetti M, Salvioni F, Barosi M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology ACE inhibitor (captopril) treatment of nephropathy in patients with insulin-dependent diabetes mellitus (IDDM). Type of intervention Secondary prevention and treatment. Economic study type Cost-effectiveness analysis. Study population Patients aged 18 to 49 years

NHS Economic Evaluation Database.1997

67. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Hendry B M, Viberti G C, Hummel S, Bagust A, Piercy J Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using an angiotensin-converting enzyme (ACE)inhibitor, captopril (25 mg, 3 times a day) to slow progression of renal failure in diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.1997

68. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction

Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction McMurray J J, McGuire A, Davie A P, Hughes D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Angiotensin Converting Enzyme (ACE) inhibitor treatment scenarios post-myocardial infarction. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients suitable for ACE inhibitor treatment after myocardial infarction. Setting Hospital. The economic study was carried out in London, UK. Dates to which data relate

NHS Economic Evaluation Database.1997